Adaptive Biotechnologies (NASDAQ:ADPT) Director Robert Hershberg Sells 30,664 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Robert Hershberg sold 30,664 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.40, for a total value of $748,201.60. Following the transaction, the director directly owned 46,683 shares of the company’s stock, valued at $1,139,065.20. This trade represents a 39.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Adaptive Biotechnologies Trading Down 0.2%

Shares of NASDAQ ADPT opened at $25.44 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $26.16. The company has a market cap of $4.06 billion, a price-to-earnings ratio of -62.05 and a beta of 2.08. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The stock’s 50 day simple moving average is $21.89 and its 200 day simple moving average is $17.28.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The company had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. During the same period in the prior year, the business earned ($0.17) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 21.5% on a year-over-year basis. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Analysts maintain a broadly constructive view, with five Buy ratings, one Hold and one Sell. BTIG Research and TD Cowen recently raised their price targets to $25 and $28, respectively, while the consensus rating remains “Moderate Buy.” Analyst and stock information
• Positive Sentiment: Institutional ownership remains high at 99.17%, and several hedge funds increased their positions, including Jennison Associates, which more than doubled its stake. Institutional ownership information
• Positive Sentiment: The company’s latest quarterly revenue reached $71.55 million, exceeding estimates of $65.44 million and increasing 21.5% year over year, supporting the growth case for its immune-receptor sequencing business. Quarterly results
• Neutral Sentiment: ADPT has rallied substantially, trading near its 52-week high and above both its 50-day and 200-day moving averages. However, the consensus price target of $24.42 is below recently reported trading levels, suggesting limited near-term upside based on current estimates.
• Negative Sentiment: Multiple insiders sold substantial positions: CEO Chad Robins sold approximately 600,000 shares for nearly $14.9 million across August 17–18, while Director Peter Neupert sold 124,690 shares for $3.14 million and Director Robert Hershberg sold 30,664 shares for $748,000. The transactions reduced the directors’ holdings by roughly 40%–49% and the CEO’s ownership by about 11%–13%, potentially weighing on investor confidence. Insider selling report
• Negative Sentiment: Adaptive Biotechnologies missed quarterly EPS expectations, reporting a loss of $0.25 per share versus the anticipated loss of $0.13. The company remains unprofitable, with analysts expecting a full-year loss of approximately $0.40 per share.

Analyst Ratings Changes

A number of research analysts have issued reports on ADPT shares. Morgan Stanley boosted their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Piper Sandler increased their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Guggenheim lifted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, JPMorgan Chase & Co. decreased their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.42.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its position in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after acquiring an additional 933 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Adaptive Biotechnologies by 6.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after purchasing an additional 941 shares during the period. Captrust Financial Advisors increased its holdings in shares of Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares during the period. Assetmark Inc. lifted its position in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after purchasing an additional 1,401 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock worth $120,000 after purchasing an additional 1,532 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.